Investigators demonstrated that dominant negative TGF-β receptor type II specifically targeting T cells decreased tumor load in tumor-bearing mice.
[Biomedicine & Pharmacotherapy]
Sorry, but the selected Zotpress account can't be found.
Sorry, but the selected Zotpress account can't be found.